Joanne Kotz

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA.

Kojin Therapeutics, Inc. operates as a small-molecule therapeutics company. It focuses on translating deep biological insight into the plasticity of human cell states to develop therapeutics for cancer, fibrosis, ischemia and immune modulation. The company was founded by Benjamin Cravatt, Stephanie K. Dougan and Stuart L.Schreiber and is headquartered in the United States.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA.

RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA.

KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA.

JPMorgan Investment Bank operates as an investment banking firm. The company is headquartered in Houston, TX.

Magnolia Neurosciences Corp. operates as a drug discovery and development company. The firm focuses on the creation of a novel class of neuroprotective medicines. The company was founded in 2018 and is headquartered in Seattle, WA.

P33 Chicago is an American private company. The firm functions as an alternative investment manager. Brad Henderson has been the CEO since 2018.

Enthera Srl develops therapeutic solutions to treat diabetes. The company was founded in 1985 by in October 2016 by Maria Gabriella Camboni, Paolo Fiorina and Francesca D'Addio and is headquartered in Milan, Italy.

Abbott Biotech Ventures, Inc. (Abbott Biotech Ventures) is a venture capital subsidiary of Abbott Laboratories. The firm is headquartered in Abbott Park, Illinois.

Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA.

Nitrase Therapeutics, Inc. develops drugs against newly discovered nitration enzyme. The firm provides disease modifying drugs for multiple additional aging-dependent diseases, such as neurodegenerative disease, heart disease and cancer. The company was founded by Irene Griswold-Prenner and is headquartered in Jackson, WY.

AbbVie Ventures LLC (AbbVie Ventures) is a venture capital firm, a subsidiary of AbbVie, Inc. founded in 2009. The firm is headquartered in North Chicago, Illinois.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Kisbee Therapeutics, Inc develops novel therapeutic agents for neurodegenerative diseases. The company was founded by Benjamin Cravatt, Jennifer Lippincott Schwartz, Emily Ricqu and Stuart L.Schreiber and is headquartered in DE.

Novartis Venture Fund provides early stage venture capital to companies in Europe, North America and Asia. The fund's focus is on the development of novel therapeutics and platforms, therefore it focuses on such sectors as Biotechnology and Biopharma. The fund makes seed and early stage investments ranging up to USD 30 million per company over its life. The fund makes follow-on and co-investments.

Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.

Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA.

Part of Pfizer Inc., Pfizer Ventures LLC is a venture capital arm that invests in areas of current or future strategic interest to Pfizer. The company is based in New York, NY. Pfizer Ventures seeks to identify and invest in emerging companies that are developing breakthroughs and technologies that have the potential to enhance Pfizer's pipeline and shape the future of the industry.

Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom.

Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA.

Magnet Biomedicine, Inc. is a biotechnology company based in Cambridge, MA. Magnet Biomedicine is advancing molecular glue discovery with rational selection and design through their TrueGlue discovery platform. The company applies cutting-edge advancements in human biology and proteomics to identify fit-for-purpose glues that maximize therapeutic impact and offer prominent benefits such as improving selectivity, inducing biological synergy on defined targets, and addressing historically undruggable proteins. Magnet Biomedicine is revolutionizing human medicine with molecular glues and is tackling multiple disease areas and biological mechanisms, including cancer, cardiovascular disease, and immune disorders. The company was founded by Benjamin F. Cravatt, Stuart L. Schreiber, Michael Rosbash, Richa Saxena.